Lipoprotein Receptor-related Protein 5, Low Density (LRP5, BMND1, HBM, HGNC:6697, LR3, LRP7, Osteoporosis Pseudoglioma Syndrome, OPPG, OPS, VBCH2)

Antibodies / Antibodies-Disease Markers

-20°C

Supplied as a lyophilized powder in PBS, 5% trehalose. Reconstitute with 500ul sterile PBS.

Recombinant corresponding to aa1422-1615 from human LRP-5 expressed in E. coli (O75197).

LRP-5 (low-density lipoprotein receptor-related protein 5) is a 1615aa, 180-200kD type I transmembrane glycoprotein. The 1353aa extracellular domain (ECD) contains 20 class B LDLR, 4 EGF-like, and 3 class A LDLR repeats. Human LRP-5aa 745-1097 encompasses class B LDLR repeats #12-17 and EGF-like repeat #3. It shares 94aa identity with mouse and rat LRP-5, and 70aa identity with human LRP-6 within corresponding regions. LRP-5 and LRP-6 mediate DKK effects on Wnt signaling. LRP-5 polymorphisms correlate with susceptibility and resistance to osteoporosis.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.